Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: John Dwyer who wrote (362)	7/27/1999 11:26:00 PM
From: tommysdad	Read Replies (1) \| Respond to of 399

"jumping all over"? Well, I'll stand by my statement that SEPR and ARQL cannot be more different, for two "biotechs" which concentrate on the "drug" side of things. If that's "jumping", call me Kermit. <<ARQL's molecules have no a priori patent problems. >> Then you know something about the libraries they are producing that most of us do not. It is highly doubtful that a company producing "drug-like" molecules does not end up making molecules that someone else has already patented. But there are ways around that . . . (use patents, for one). <<one reason I like PCOP so much is that they have in-house R&D programs and a UHTS program>> That, among other things, is what I don't like about PCOP. "One-stop shopping"? No, thanks. Do one thing well and do it over and over and over again. At the very least, we're keeping the ARQL thread active, which is good.